# TEXAS HEALTH AND HUMAN SERVICES COMMISSION
# RATE ANALYSIS DEPARTMENT

## Proposed Medicaid Payment Rates for Annual 2016 Healthcare Common Procedure Coding System (HCPCS) Updates:

## (1) Clinical Diagnostic Laboratory Services - Drug Testing and Therapeutic Drug Assays

### Payment rates are proposed to be effective May 1, 2016

## SUMMARY OF PROPOSED MEDICAID PAYMENT RATES

## Effective May 1, 2016

Included in this document is information relating to the proposed Medicaid payment rates for Annual Healthcare Common Procedure Coding System (HCPCS) Updates for Clinical Diagnostic Laboratory Services Drug Testing and Therapeutic Drug Assays. The rates are proposed to be effective May 1, 2016.

## Hearing

The Health and Human Services Commission (HHSC) will conduct a public hearing to receive comments regarding the proposed Medicaid rates detailed in this document on May 11, 2016, at 1:30 p.m. in the Public Hearing Room in the Brown-Heatly Building at 4900 North Lamar Boulevard, Austin, Texas 78751, with entrance through Security at the front of the building facing Lamar Boulevard. HHSC will consider concerns expressed at the hearing prior to final rate approval. This public hearing is held in compliance with the provisions of Human Resources Code §32.0282 and the Texas Administrative Code, Title 1 (1 TAC), §355.201, which require a public hearing on proposed payment rates. Should you have any questions regarding the information in this document, please contact:

Leslie Cisneros, Hospital Rate Analysis
Texas Health and Human Services Commission
(512) 428-1962; FAX: (512) 730-7475
E-mail: leslie.cisneros@hhsc.state.tx.us

HHSC also will broadcast the public hearing; the broadcast can be accessed at http://www.hhsc.state.tx.us/news/meetings.asp. The broadcast will be archived and can be accessed on demand at the same website.

## Background

HHSC is responsible for the reimbursement determination functions for the Texas Medicaid Program. Proposed rates are calculated utilizing established methodologies that conform to the Social Security Act and related federal regulations, the federally approved Texas Medicaid State Plan, all applicable state statutes and rules, and other requirements. HHSC reviews the Medicaid reimbursement rates for all acute care services every two years. These biennial reviews result in rates that are increased, decreased, or remain the same. The reviews are conducted to ensure that rates continue to be based on established rate methodologies.

## Methodology

The specific administrative rules that govern the establishment of the fees in this proposal include these rules in 1 TAC §355.8610, which addresses the reimbursement

methodology for Clinical Laboratory Services.

## **Proposed Rates**

The methodologies used to determine the proposed fee-for-service Medicaid rates are summarized below:

- Procedure codes and descriptions used in the Texas Medicaid Program are national standard code sets as required by federal laws; Healthcare Common Procedural Coding System (HCPCS) and Current Procedural Terminology (CPT).

- Rate determination methodologies related to clinical laboratory services are addressed in §355.8610

Proposed payment rates are listed in the attachment outlined below:

Annual 2016 HCPCS Updates Att - Clin Diag Lab Svcs

This public rate hearing briefing packet presents proposed payment rates and is distributed at HHSC public rate hearings and posted by the proposed effective date on the HHSC website at http://www.hhsc.state.tx.us/rad/rate-packets.shtml.  Proposed rates may or may not be adopted, depending on HHSC management decisions after review of public comments and additional information.  Provider and public notification about adoption decisions are published on the Texas Medicaid and Healthcare Partnership (TMHP) website at http://www.tmhp.com in banner messages, bulletins, notices, and updates to the Texas Medicaid fee schedules.  The fees schedules are available in static files or online lookup at http://public.tmhp.com/FeeSchedules.

# Annual 2016 HCPCS Update Att - CLINICAL DIAGNOSTIC LABORATORY FEES Drug Testing and Therapeutic Drug Assays - (proposed to be effective May 1, 2016)

| TOS * | Procedure Code | Long Description ** | Age Range | Clinical Laboratory Current Fee | Clinical Laboratory Proposed Medicaid Fee | Sole Community Current Fee | Sole Community Proposed Medicaid Fee | Department of State Health Services Current Fee | Department of State Health Services Proposed Medicaid Fee |
|---|---|---|---|---|---|---|---|---|---|
| 5 | G0477 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service | 0-999 | Not a Benefit | $9.54 | Not a Benefit | $9.86 | Not a Benefit | $11.36 |
| 5 | G0478 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) read by instrument-assisted direct optical observation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service | 0-999 | Not a Benefit | $12.73 | Not a Benefit | $13.15 | Not a Benefit | $15.15 |
| 5 | G0479 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service | 0-999 | Not a Benefit | $50.90 | Not a Benefit | $52.60 | Not a Benefit | $60.60 |
| 5 | G0480 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 1-7 drug class(es), including metabolite(s) if performed. | 0-999 | Not a Benefit | $67.15 | Not a Benefit | $69.38 | Not a Benefit | $79.94 |
| 5 | G0481 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 8-14 drug class(es), including metabolite(s) if performed | 0-999 | Not a Benefit | $103.31 | Not a Benefit | $106.76 | Not a Benefit | $122.99 |
| 5 | G0482 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 15-21 drug class(es), including metabolite(s) if performed | 0-999 | Not a Benefit | $139.47 | Not a Benefit | $144.11 | Not a Benefit | $166.03 |
| 5 | G0483 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 22 or more drug class(es), including metabolite(s) if performed | 0-999 | Not a Benefit | $180.79 | Not a Benefit | $186.82 | Not a Benefit | $215.23 |

| *Type of Service (TOS) | |
|---|---|
| 5 | Clinical Laboratory Services |

** **Required Notice:** The five-character code included in this notice is obtained from the Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physicians. The responsibility for the content of this notice is with HHSC and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in this notice. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained.